Programmed cell death protein 1 (PD-1) on T lymphocytes and its main ligand (PD-L1) on tumor cells are the targets of antibody-based interventions aimed at reactivating latent anti-tumor immunity. This evidence concerns the gene PDCD1 and neoplasm.